Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
OFD Life Sciences, a division of Oregon Freeze Dry, has been awarded a patent for its LyoPastille oral delivery platform, an orally dissolving tablet (ODT) technology.
read more
Wednesday, February 18, 2026
OFD Life Sciences, a division of Oregon Freeze Dry, announced that Danielle Grosso has joined the organization as the Senior Director of Project Management.
read more
OcyonBio announced a manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc. OcyonBio is creating an advanced therapy contract development, manufacturing organization (CDMO) that provides ...
read more
AGC Biologics has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.
read more
Octapharma and BioMatrix Specialty Pharmacy are supporting a new study focused on treating patients with COVID-19 and presenting with COVID-19-associated myocardial dysfunction.
read more
Octapharma USA is extending funding for an IIS focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
read more
Thursday, February 16, 2012
Ockham, a leading, global full-service contract research organization (CRO) with a focus in oncology, today announces it has completed the acquisition of Nexus Oncology. The transaction also provides Ockham with an institutional investment partner.
read more
OcellO has entered an agreement to provide in vitro research services to Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics.
read more
Oakrum Pharma has entered into an agreement with Biophore to develop and manufacture two prescription generic pharmaceutical products that are intended to be commercialized in the U.S.
read more
Wednesday, March 24, 2021
Oakrum, in collaboration with Aucta, announced the U.S. approval of a generic version of JADENU Sprinkle in 90mg, 180mg, and 360mg strengths.
read more
Monday, February 25, 2019
Oakrum Pharma has entered into an agreement with Aucta to develop and manufacture four prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label.
read more
Nykode Therapeutic, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston.
read more
Friday, February 07, 2014
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
(“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune
therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of
NW Bio, will ...
read more
Friday, February 07, 2014
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio),
a biotechnology company developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that it has entered into a set of agreements for large-scale expansion of
the ...
read more
Monday, February 08, 2016
Nuvo Research has agreed with Horizon Pharma to extend the term of their manufacturing agreement for the production of PENNSAID® 2% for the U.S. market to December 31, 2029, which extends the agreement by an additional seven years.
read more